OneSource Specialty Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
OneSource Specialty Pharma is navigating a pivotal phase characterized by a robust recovery in revenue, primarily driven by the successful launch of generic semaglutide and an aggressive expansion of its manufacturing capabilities. Management's focus on organic growth, targeting $400 million in revenue by FY28, underscores their commitment to enhancing margins through operational leverage as commercial volumes increase. The strategic shift towards biologics and higher-margin revenue models positions the company favorably for long-term growth, despite potential headwinds from pricing pressures and regulatory compliance risks. Vista's financial outlook reflects these developments, anticipating improved margins and a stable revenue trajectory, although the current valuation suggests limited upside given the execution risks associated with capacity expansion. The macro environment remains supportive, with favorable liquidity conditions in India, although raw material supply constraints could pose challenges. Over the next 12-24 months, key opportunities include scaling biologics and leveraging regulatory compliance, while watchpoints include the timing of international approvals and the execution of the capacity expansion roadmap
Why We Like This Stock
- Successful launch of generic semaglutide enhances revenue visibility and market share
- Aggressive capacity expansion in sterile injectables and biologics supports long-term growth
- Management's focus on organic growth and operational leverage is expected to improve margins
Things To Watch Out For
- Potential pricing pressures could impact margins in a competitive landscape
- Execution risks associated with large-scale capacity additions may hinder growth targets
- Regulatory compliance challenges could delay market entry for new products
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 172 | 1,445 | 1,422 | 1,499 | 1,967 |
| Profit Before Tax (Cr.) | -244 | 44 | -82 | 196 | 230 |
| PBT Margin | -141.9% | 3.0% | -576.7% | 13.1% | 11.7% |
| Net Profit (Cr.) | -269 | 99 | -84 | 147 | 173 |
| Earnings Per Share | -23.5 | 8.6 | -7.4 | 12.8 | 15.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 2,400 | 27-Jul-2026 |
Company Overview
Show Company Profile
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.